BrainStorm Cell Therapeutics met with U.S. Food and Drug Administration (FDA) officials regarding its plans for a semi-automatic manufacturing process for NurOwn, the company’s investigational cell-based therapy for amyotrophic lateral sclerosis (ALS). Discussion at the meeting — formally called a type C meeting — covered issues that included how to evaluate future therapy modifications for comparability testing, as well as the logistics involved in sourcing starter materials and of future manufacturing production. “We are pleased…

You must be logged in to read/download the full post.